Impact of vancomycin treatment duration and dose on kidney injury

International Journal of Antimicrobial Agents

Volumn 43, Issue 3, 2014, Pages 297-298

  Bosch, Kirsten ^a   McLaughlin, Milena M ^b,c   Esterly, John S ^b,d   Rhodes, Nathaniel J ^b,c   Postelnick, Michael J ^b   Scheetz, Marc H ^b,c  

^a Department of Education and Professional Development   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

^d CHICAGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; CREATININE; LINEZOLID; VANCOMYCIN;

AGE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; HUMAN; INCIDENCE; KIDNEY INJURY; LETTER; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEX; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TIME FACTORS; VANCOMYCIN; YOUNG ADULT;

EID: 84896495649     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.11.004     Document Type: Letter

References (5)

1. M. Rybak, B. Lomaestro, J.C. Rotschafer, R. Moellering Jr., W. Craig, and M. Billeter et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98 [Erratum in: Am J Health Syst Pharm 2009;66:887]
2. R. Kullar, S.L. Davis, D.P. Levine, and M.J. Rybak Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets Clin Infect Dis 52 2011 975 981
3. S.J. van Hal, D.L. Paterson, and T.P. Lodise Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter Antimicrob Agents Chemother 57 2013 734 744
4. J.S. Esterly, J. Wagner, M.M. McLaughlin, M.J. Postelnick, C. Qi, and M.H. Scheetz Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification Antimicrob Agents Chemother 56 2012 4885 4890
5. A. Wong-Beringer, J. Joo, E. Tse, and P. Beringer Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy Int J Antimicrob Agents 37 2011 95 101